Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis by pancreatic duct stenting using a loop-tipped guidewire

Table 1 Patient clinical background

	Loop-type guidewire (Group A)	Straight-type guidewire (Group B)	P-value
n	20	20
Age	71.68 ± 9.53 (43-85)	71.63 ± 10.36 (39-80)	NS
Sex	Males 10, females 10	Males 10, females 10	NS
Disease
Bile duct stone	12	12	NS
Cholangiocarcinoma	3	3	NS
Pancreatic cancer	3	2	NS
Gallbladder cancer	1	2	NS
Intraductal papillary mucinous neoplasm	1	1	NS
Diagnostic ERCP	1	1	NS
Therapeutic ERCP	19	19	NS

ERCP: Endoscopic retrograde cholangiopancreatography; NS: Not significant.

Table 2 Procedures conducted

	Loop-type guidewire (Group A)	Straight-type guidewire (Group B)	P-value
P-GW	5	6	NS
P-GW + TPPP	15	14	NS
Endoscopic sphincterotomy	19	19	NS
Lithotomy	12	12	NS
Biliary stenting	7	7	NS
Intraductal ultrasonography	1	1	NS
Biopsy of the bile duct	1	1	NS
Pancreatic duct stenting	20	20	NS
Pancreatic duct injection	1.263 ± 0.562	1.286 ± 0.588	NS
	(1-3)	(1-3)
Cannulation time (min)	33.45 ± 9.72	34.9 ± 97.04	NS
	(16-50)	(16-50)
Procedure time (min)	44.2 ± 13.22	46.8 ± 14.03	NS
	(23-70)	(20-63)

TPPP: Transpancreatic precut papillotomy; NS: Not significant; P-GW: Guidewire-placing method.

Table 3 Complications and other events

	Loop-type guidewire (Group A)	Straight-type guidewire (Group B)	P-value
Bleeding	0	0	-
Perforation	0	0	-
Pancreatitis	0	1	NS
Pre-ERCP amylase level	72.84 ± 20.63	72.75 ± 20.40	NS
	(41-112)	(43-120)
Post-ERCP amylase level	257.15 ± 136.44	552.05 ± 534.57	< 0.05
	(88-628)	(101-2389)
Frequency of unintended insertion of the guidewire into a side branch of the pancreatic duct	0.056 ± 0.23	2.3 ± 1.84	< 0.05
	(0-1)	(0-5)
Hyperamylasemia	2	9	< 0.05
Others	0	0	-

ERCP: Endoscopic retrograde cholangiopancreatography; NS: Not significant.